Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications

<p>– Recludix to receive $125 million in near-term payments and potentially more than $1.2 billion subject to future milestones, and up to double-digit royalties on sales – – Recludix to lead research and development until start of Phase 2 – – Recludix has an option to participate equally in U.S. profit/loss sharing – SAN DIEGO, […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/recludix-pharma-enters-into-a-strategic-collaboration-with-sanofi-to-advance-novel-oral-stat6-inhibitor-in-multiple-immunological-and-inflammatory-indications/">Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>